A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.
Expert opinion on biological therapy（2023）
摘要
Findings were consistent with the known CT-P10/reference rituximab safety profile, with high effectiveness observed in NHL/CLL and RA.
更多查看译文
关键词
CT-P10,Chronic lymphocytic leukemia,granulomatosis with polyangiitis,microscopic polyangiitis,non-Hodgkin’s lymphoma,rheumatoid arthritis,rituximab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要